Genelux Corp Banner Image

Genelux Corp

  • Ticker GNLX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Genelux Corp Logo Image
  • 11-50 Employees
  • Based in Westlake Village, California
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Their ChoiceTM Discovery Platform is the foundation of their oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, their lead product candidate is currently inMore a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. They are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about their investigational products and clinical trials can be found here.
5.0 / 5.0 (2)

Genelux Corp reports have an aggregate usefulness score of 5.0 based on 2 reviews.

Genelux Corp

Most Recent Annual Report

Genelux Corp
MOST RECENT 2022 Annual Report and Form 10K
Genelux Corp Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!